Drug developer plans to go public.

• Position: Regional Report - ICAgen Inc. plans to issue initial public offering - Brief Article

Icagen, a Durham-based drug developer, has filed plans with the U.S. Securities and Exchange Commission to raise $86.3 million in an initial public offering. The company, which asked for the symbol ICGN, didn't disclose an offering price for its shares. Icagen, which was founded in 1992 and has 65 employees, is working on four drugs, including a treatment for sickle-cell anemia that is expected to begin final human testing by...